AB | BC | MB | NB | NL | NS | NT | ON | PE | QC | SK | YT
Search National Drug Schedules Member Login

What's New

Pharmacy Technician Bridging Education Program-Course and PLAR exam schedules

Please note, this section will be updated periodically as the information becomes available.

 

  Reminder: Courses and PLAR exams available in both English and French

    NOTE: Selkirk College registration deadline for all English and French courses beginning in September 2016 is August 25, 2016

____________________________
 

        Rappel :  Les cours et les examens ERA sont offerts en français et en anglais

  REMARQUE :  La date limite pour l’inscription aux cours (anglais et français) débutant en septembre 2016 au collège Selkirk est le 25 août 2016 

Registration deadlines for all institutions are available on the Course and PLAR Schedules page.

Registration for all courses is conducted directly with the educational institution offering the program.

NDSAC Meeting of September 12-13, 2016

The proposed meeting of the National Drug Scheduling Advisory Committee (NDSAC) for September 12-13, 2016 is cancelled.

The next meeting of the Committee is scheduled for December 5-6, 2016. The deadline to receive submissions for a drug scheduling application for this meeting is by end of day Thursday, October 6, 2016.

Health Product Risk Communication

REVOLADE (eltrombopag) - Risk of Severe Hepatotoxicity - Novartis Pharma Canada Inc.

REVOLADE administration can cause severe hepatotoxicity and potentially fatal liver injury. Cases of severe drug-induced liver injury with REVOLADE have been reported in patients during clinical trials and post-marketing.

Health Canada Health Product Risk Communication

Health Product Risk Communication

ADEMPAS (riociguat) - New Contraindication for Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias (PH-IIP) - Bayer Inc.

Patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)should not be treated with ADEMPAS. The RISE-IIP study, which was investigating the effects of ADEMPAS in patients with PH-IIP, has been terminated early due to an increased risk of mortality and serious adverse events among subjects with PH-IIP receiving ADEMPAS.

Health Canada Health Product Risk Communication

Health Product InfoWatch

The August issue of the Health Product InfoWatch published by Health Canada is now available. This monthly publication provides clinically relevant safety information on pharmaceuticals, biologics, medical devices and natural health products. Please consult the index for a complete listing of previous issues.

Foreign Product Alert

Health Canada is advising Canadians not to use these foreign health products as they may pose a health risk. These products have been found by regulators in other countries to contain undeclared drug ingredients. Prescription drugs should only be taken under the supervision of a health care practitioner.

These products are not authorized for sale in Canada and have not been found on the Canadian market, but they may have been brought into the country by travellers or purchased over the Internet.

[> More]

 

NOW AVAILABLE!
SITE MAINTENANT DISPONIBLE!

Gateway for international
pharmacists
Portail pour pharmaciens
formés à l’étranger

 

 

 

National Pharmacy Technician Bridging Education Program

Students and educational institutions can find more information about NAPRA's newest program.


NDSAC Drug Scheduling Applications

Find information about the NDSAC process and how to prepare scheduling applications.